Committee backs compounding-clarity bill to protect patient access to compounded medicines

The Health and Human Services Committee approved House Bill 12-62 on a favorable recommendation and sent it to the Committee of the Whole, after extensive testimony from hospitals, compounding pharmacies and medical groups.

Sponsors said litigation nationwide and pressure from manufacturers have created uncertainty for compounding pharmacies and hospitals that rely on personalized formulations. “House Bill 12-62 helps provide the clarity needed so that this long-standing and regulated part of patient care can continue,” Representative R. Stewart said, outlining that the bill clarifies compounding under federal frameworks and preserves Board of Pharmacy oversight.

Support from health systems and compounding providers was broad: witnesses included Mark Wagner of the Outsourcing Facilities Association, Mark Speaker of Stack Pharma, Kristen Youngdahl of Belmar Pharma, and representatives of Children’s Hospital Colorado and the Colorado Medical Society. They described compounding’s role in producing pediatric liquid formulations, concentrated albuterol used during shortages, total parenteral nutrition components and individualized hormone therapies. Speakers said aligning state statute with federal law would prevent duplicative state rules that could hinder access, especially in rural areas.

Committee members raised detailed questions about safety oversight, interactions with FDA rulemaking and the board’s authority; witnesses said the bill explicitly points to federal standards and existing inspection and USP quality frameworks, and that both 503A (patient-specific) and 503B (registered outsourcing) practices are covered.

The committee voted to advance the bill. Sponsors said they will continue to work on clarifying language about technical references to federal sections and the interplay with board rules.

Next steps: HB12-62 advances to the Committee of the Whole; if enacted it would affirm that compounding pharmacies operating in compliance with federal and state law may supply compounded medications consistent with federal oversight, with the goal of preserving access for hospitals and patients.